Insider transactions

Geoffrey M. Parker

CIK 1491874 · CHIEF FINANCIAL OFFICER · last filed 2026-09-15

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$2.50M
Companies
9
Total Filings
132
Lifetime Open-Market Net
$5.82M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

TCDA price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
15 RIORDAN PLACE
MENLO PARK, CA 94025
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PRGO Director 51,855 $16.17 $838.5K $1.63M 33 2026-09-15
ALLO CHIEF FINANCIAL OFFICER 1,252,795 $1.33 $1.67M -$95.3K 9 2026-02-04
Better Therapeutics, Inc. (BTTX) Delisted Director 1,085,138 $0.04 $48.4K $917.2K 9 2023-12-20
CCXI Director 0 $10.36 $0 -$2.61M 25 2022-10-24
Tricida, Inc. (TCDA) Delisted COO, CFO and EVP 118,617 $0.11 $12.8K $4.25M 17 2022-03-02
GENOMIC HEALTH INC (GHDX) Delisted Director 955 — — $0 4 2019-06-18
Viracta Therapeutics, Inc. (SNSS) Delisted Director 385 $18.62 $7.2K $58.2K 6 2017-06-02
Anacor Pharmaceuticals, Inc. (ANAC) Delisted Executive Vice President & CFO 104,840 $10.19 $1.07M $1.67M 20 2015-03-23
GENOPTIX INC (GXDX) Delisted Director 4,167 — — $0 4 2011-03-01

Recent Filings · Page 10 of 14

132 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2016-12-12 Viracta Therapeutics, Inc. (SNSS) Delisted Buy (P) +3,740 $14.5K EDGAR
2016-11-21 PRGO Buy (P) +2,500 $221.9K EDGAR
2016-11-18 PRGO Grant (A) — $0 EDGAR
2016-06-23 GENOMIC HEALTH INC (GHDX) Delisted Grant (A) — $0 EDGAR
2016-05-27 CCXI Grant (A) — $0 EDGAR
2016-05-27 Viracta Therapeutics, Inc. (SNSS) Delisted Buy (P) +9,500 $4.5K EDGAR
2016-05-26 Viracta Therapeutics, Inc. (SNSS) Delisted Buy (P) +52,505 $24.8K EDGAR
2016-05-24 CCXI Exer (M) +11,795 $0 EDGAR
2016-05-13 CCXI Buy (P) +40,000 $161.4K EDGAR
2016-04-01 Viracta Therapeutics, Inc. (SNSS) Delisted Grant (A) — $0 EDGAR
Showing 91–100 of 132
Page 10 of 14
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.